The pathophysiology of thyroid eye disease: implications for immunotherapy

Area of Science:

• Immunology
• Ophthalmology
• Endocrinology

Background:

• Thyroid eye disease (TED) is an autoimmune condition often linked to Graves' disease.
• Current treatments for TED primarily manage symptoms without altering disease progression.
• Understanding the underlying immunopathogenesis is crucial for developing effective therapies.

Purpose of the Study:

• To review current knowledge on the immunopathogenesis of TED.
• To explore potential targeted immunotherapies for TED.

Main Methods:

• Review of existing literature on TED immunopathogenesis.
• Analysis of the role of orbital fibroblasts and fibrocytes.
• Evaluation of data on targeted immunotherapies, including Rituximab (RTX).

Main Results:

• Orbital fibroblasts and bone marrow-derived fibrocytes play key roles in TED pathogenesis.
• Rituximab (RTX), a B-cell depleting agent, has shown encouraging sustained clinical responses in TED.
• RTX's efficacy may involve modulation of antigen presentation, independent of B-cell levels or antibody production.

Conclusions:

• Advances in understanding TED immunopathogenesis are driving clinical trials for targeted immune therapies.
• Further research into molecular mechanisms will lead to expanded treatment options for TED.
• Targeted therapies may reduce the need for reconstructive surgery in TED patients.